Breast cancer subtypes in transplant patients: Does it really matter?

2021 ◽  
Author(s):  
Kadri Altundag
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Transplant Patients

Identification of new therapeutic leads for triple negative breast cancer subtypes

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Therapeutic Leads

scholarly journals Clinical Significance of Annexin A2 Expression in Breast Cancer Patients

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 2
Author(s):  
Lee D. Gibbs ◽  
Kelsey Mansheim ◽  
Sayantan Maji ◽  
Rajesh Nandy ◽  
Cheryl M. Lewis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Cell Lines ◽  
Breast Cancer Subtypes ◽  
Enzyme Linked Immunosorbent Assay ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Cancer Subtypes ◽  
Tumor Tissues

Increasing evidence suggests that AnxA2 contributes to invasion and metastasis of breast cancer. However, the clinical significance of AnxA2 expression in breast cancer has not been reported. The expression of AnxA2 in cell lines, tumor tissues, and serum samples of breast cancer patients were analyzed by immunoblotting, immunohistochemistry, and enzyme-linked immunosorbent assay, respectively. We found that AnxA2 was significantly upregulated in tumor tissues and serum samples of breast cancer patients compared with normal controls. The high expression of serum AnxA2 was significantly associated with tumor grades and poor survival of the breast cancer patients. Based on molecular subtypes, AnxA2 expression was significantly elevated in tumor tissues and serum samples of triple-negative breast cancer (TNBC) patients compared with other breast cancer subtypes. Our analyses on breast cancer cell lines demonstrated that secretion of AnxA2 is associated with its tyrosine 23 (Tyr23) phosphorylation in cells. The expression of non-phosphomimetic mutant of AnxA2 in HCC1395 cells inhibits its secretion from cells compared to wild-type AnxA2, which further suggest that Tyr23 phosphorylation is a critical step for AnxA2 secretion from TNBC cells. Our analysis of AnxA2 phosphorylation in clinical samples further confirmed that the phosphorylation of AnxA2 at Tyr23 was high in tumor tissues of TNBC patients compared to matched adjacent non-tumorigenic breast tissues. Furthermore, we observed that the diagnostic value of serum AnxA2 was significantly high in TNBC compared with other breast cancer subtypes. These findings suggest that serum AnxA2 concentration could be a potential diagnostic biomarker for TNBC patients.

scholarly journals Breast Cancer Subtypes in Asian-Americans Differ According to Asian Ethnic Group

2012 ◽  
Vol 14 (5) ◽  
pp. 754-758 ◽  
Author(s):  
Ellen Chuang ◽  
Paul Christos ◽  
Arielle Flam ◽  
Katherine McCarville ◽  
Melissa Forst ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ethnic Group ◽  
Asian Americans ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments

2011 ◽  
Vol 130 (2) ◽  
pp. 489-498 ◽  
Author(s):  
Yahong Wang ◽  
Quangui Yin ◽  
Qi Yu ◽  
Jing Zhang ◽  
Ziyu Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Risk Of Relapse

Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes

2022 ◽  
Author(s):  
Ana Carolina Pavanelli ◽  
Flavia Rotea Mangone ◽  
Piriya Yoganathan ◽  
Simone Aparecida Bessa ◽  
Suely Nonogaki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immunohistochemical Analysis ◽  
Breast Cancer Subtypes ◽  
Luminal A ◽  
Cancer Subtypes
Sign in / Sign up

Export Citation Format

Share Document